Novo-backed MapLight valued at $787 million after shares jump in Nasdaq debut

(Reuters) -MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company to go public under a rarely used regulatory provision since the start of the U. Shares of the Redwood City, California-based company, which is developing treatments for central nervous system disorders, opened at $19 apiece, nearly 12% above the initial public offering price of $17.